News

Results from an ongoing Phase 1/2 clinical trial testing Cabaletta Bio‘s experimental cell therapy rese-cel (resecabtagene autoleucel) in adults with myasthenia gravis (MG) are expected in the second half of 2026. That’s according to a press release from Cabaletta, where the company reported its latest financial and…

Fifteen college or trade school scholarships are now available for people with myasthenia gravis (MG) and their immediate family members through the second annual UCB U.S. Myasthenia Gravis Scholarship program. The scholarships, worth up to $10,000, will help ease the financial burden of continuing education or career training…

A single dose of KYV-101, a cell therapy being developed by Kyverna Therapeutics for generalized myasthenia gravis (gMG), led to rapid and sustained reductions in symptom severity — lasting up to six months thus far — in adults with gMG. That’s according to data from an interim…

Nearly one year of treatment with Remegen’s telitacicept in a clinical trial in China led to substantial and sustained reductions in symptom severity among adults with generalized myasthenia gravis (gMG). That’s according to new results from the Phase 3 trial, which were shared during the Myasthenia Gravis…

Treatment with Imaavy (nipocalimab-aahu) has led to sustained disease control for up to 1.5 years among adolescents with generalized myasthenia gravis (gMG), according to data from the long-term extension (LTE) part of a Phase 2/3 clinical trial. The study, called Vibrance-MG (NCT05265273), is now evaluating Imaavy’s safety…

Weekly treatment with gefurulimab —an investigational C5 inhibitor from Alexion, Astrazeneca Rare Disease, that’s designed to be self-administered — led to early and sustained reductions in disease severity for adults with generalized myasthenia gravis (gMG), according to top-line data from a Phase 3 clinical trial. The findings…

Vyvgart (efgartigimod alfa-fcab) led to significant and clinically meaningful reductions in disease severity among adults with generalized myasthenia gravis (gMG) who test negative for disease-causing antibodies targeting the acetylcholine receptor (AChR). Notably, benefits were seen across different subgroups of anti-AChR antibody-negative patients, who are also known as having…

Vyvgart (efgartigimod alfa-fcab), currently approved in the U.S. for treating certain adults with generalized myasthenia gravis (gMG), safely eased disease severity in adolescents with the disease, according to new data from a Phase 2/3 trial. Called ADAPT JR (NCT04833894), the study is still recruiting younger children,…

Facing the daily challenges of myasthenia gravis (MG) requires more than medication: It demands diligent self-management, including careful attention to stress and rest, and a cautious navigation of the digital world. Those are the main takeaways from the webinar, “Pushing Back at MG: From Getting Informed to…

People who recover from myasthenia gravis (MG) after long-term treatment have higher numbers of certain subsets of monocytes — a type of immune cell — and lower numbers of others, a small study in China found. “Consistent with previous studies, our study further validated that dysregulation of immune cells,…